Innospec Inc. (IOSP) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Innospec’s revenue went from $883M in fiscal 2016 to $1.8B in fiscal 2025, growth of about 8.1% a year.
Net income in fiscal 2025 was $117M, a net margin of 6.6%; the best year in this period was 2023 with $139M.
Over the twelve months to September 30, 2026, revenue was $1.9B and net income $140M.
Free cash flow was $88M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count rose 2% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9B | $1.8B | $1.8B | $1.9B | $2.0B | $1.5B | $1.2B | $1.5B | $1.5B | $1.3B | $883M |
| Gross profit | $518M | $492M | $543M | $591M | $587M | $435M | $343M | $466M | $435M | $403M | $332M |
| Operating income | $165M | $130M | $178M | $162M | $187M | $132M | $34M | $150M | $134M | $125M | $98M |
| Net income | $140M | $117M | $36M | $139M | $133M | $93M | $29M | $112M | $85M | $62M | $81M |
| EPS (diluted) | $5.67 | $4.67 | $1.42 | $5.56 | $5.32 | $3.75 | $1.16 | $4.54 | $3.45 | $2.52 | $3.33 |
| R&D | $55M | $51M | $56M | $49M | $39M | $37M | $31M | $35M | $33M | $31M | $25M |
| Revenue growth | — | −3.6% | −5.3% | −0.8% | +32.4% | +24.3% | −21.2% | +2.5% | +13.0% | +47.9% | −12.7% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $103M | $138M | $184M | $207M | $82M | $93M | $146M | $162M | $105M | $83M | $106M |
| Capital spending | -$57M | -$50M | -$41M | -$62M | -$40M | -$39M | -$30M | -$30M | -$29M | -$23M | -$16M |
| Free cash flow | $46M | $88M | $143M | $145M | $42M | $54M | $116M | $132M | $76M | $59M | $89M |
| Dividends paid | $44M | $42M | $39M | $35M | $32M | $29M | $26M | $25M | $22M | $19M | $16M |
| Buybacks | $14M | $24M | $700000 | $1M | $6M | $800000 | $2M | $2M | $1M | $1M | $8M |
| Stock-based pay | $8M | $8M | $8M | $8M | $7M | $4M | $6M | $7M | $5M | $4M | $3M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $292M | $289M | $204M | $147M | $142M | $105M | $76M | $123M | $90M | $102M |
| Debt | — | $53M | $45M | $45M | $45M | $36M | $40M | $91M | $208M | $218M | $269M |
| Equity | — | $1.3B | $1.2B | $1.1B | $1.0B | $1.0B | $944M | $918M | $825M | $794M | $654M |
| Total assets | — | $1.8B | $1.7B | $1.7B | $1.6B | $1.6B | $1.4B | $1.5B | $1.5B | $1.4B | $1.2B |
| Shares (diluted) | 25M | 25M | 25M | 25M | 25M | 25M | 25M | 25M | 25M | 24M | 24M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 27.7% | 27.7% | 29.4% | 30.3% | 29.9% | 29.3% | 28.7% | 30.8% | 29.4% | 30.9% | 37.6% |
| Operating margin | 8.8% | 7.3% | 9.6% | 8.3% | 9.5% | 8.9% | 2.8% | 9.9% | 9.0% | 9.6% | 11.1% |
| Net margin | 7.5% | 6.6% | 1.9% | 7.1% | 6.8% | 6.3% | 2.4% | 7.4% | 5.8% | 4.7% | 9.2% |
| FCF margin | 2.4% | 5.0% | 7.8% | 7.4% | 2.1% | 3.6% | 9.7% | 8.7% | 5.1% | 4.5% | 10.1% |
| ROIC | — | 7.9% | 12.2% | 10.8% | 12.5% | 8.6% | 2.5% | 11.1% | 8.3% | 9.8% | 8.4% |
| ROE | — | 8.8% | 2.9% | 12.1% | 12.8% | 9.0% | 3.0% | 12.2% | 10.3% | 7.8% | 12.4% |
Frequently asked questions
What is Innospec’s annual revenue?
$1.8B in fiscal 2025 and $1.9B over the twelve months to September 30, 2026.
How much profit does Innospec make?
Net income was $117M in fiscal 2025 (net margin 6.6%).
Is Innospec’s revenue growing?
No: revenue fell 3.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.